The American Association of Oral and Maxillofacial Surgeons recently updated management recommendations and related information for osteonecrosis of the jaw. The condition formerly referred to as bisphosphonate-related osteonecrosis of the jaw (BRONJ) was renamed medication-related osteonecrosis of the jaw (MRONJ) due to reports of several non-bisphosphonate drugs resulting in the loss of alveolar bone and clinically appearing similar to BRONJ. This course will cover new information on proposed etiologies, mechanisms of drug actions and physical events which may be related to development of the loss of alveolar bone. All pharmacologic agents proposed to play a role in the development of the alveolar bone destruction will be identified and the degree of risk for each agent discussed. Information to discuss with patients taking medications associated with MRONJ are included to assist in patient information identified in the AAOMS guidelines.